Levodopa-induced Dyskinesia: A Brief Review of the Ongoing Clinical Trials
- 23 December 2021
- journal article
- review article
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 12 (2) , 51-55
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Kynurenines in the CNS: recent advances and new questionsNature Reviews Drug Discovery, 2012
- Effects of Chinese herbal medicine Tianqi Pingchan Granule on G protein-coupled receptor kinase 6 involved in the prevention of levodopa-induced dyskinesia in rats with Parkinson diseaseJournal of Chinese Integrative Medicine, 2012
- The serotonergic system in Parkinson's diseaseProgress in Neurobiology, 2011
- The 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitor Lovastatin Reduces Severity of l-DOPA-Induced Abnormal Involuntary Movements in Experimental Parkinson's DiseaseJournal of Neuroscience, 2008
- Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trialMovement Disorders, 2006
- Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 yearsMovement Disorders, 2004
- Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosetsPharmacology Biochemistry and Behavior, 2004
- Clozapine-Induced Agranulocytosis -- Incidence and Risk Factors in the United StatesNew England Journal of Medicine, 1993
- Buspirone in the treatment of levodopa induced dyskinesias.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- NEUROCHEMICAL PROFILE OF ELTOPRAZINEDrug Metabolism and Drug Interactions, 1990